Monopar Therapeutics received FDA Rare Pediatric Disease designation for ALXN1840, potentially enabling a pediatric Priority Review Voucher upon NDA approval.
Key Highlights:
- FDA granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline) for Wilson disease.
- Designation could make the company eligible for a pediatric Priority Review Voucher if ALXN1840's NDA is approved.
- Priority review can shorten FDA review time by several months, accelerating potential market access.
- ALXN1840 is a once-daily oral therapy that in Phase 3 showed sustained copper mobilization vs standard of care.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.